Literature DB >> 23447584

A novel population of cholinergic neurons in the macaque spinal dorsal horn of potential clinical relevance for pain therapy.

Sophie Anne Pawlowski1, Stéphane Gaillard, Imad Ghorayeb, Alfredo Ribeiro-da-Silva, Rémy Schlichter, Matilde Cordero-Erausquin.   

Abstract

Endogenous acetylcholine (ACh) is a well-known modulator of nociceptive transmission in the spinal cord of rodents. It arises mainly from a sparse population of cholinergic interneurons located in the dorsal horn of the spinal cord. This population was thought to be absent from the spinal cord of monkey, what might suggest that spinal ACh would not be a relevant clinical target for pain therapy. In humans, however, pain responses can be modulated by spinal ACh, as evidenced by the increasingly used analgesic procedure (for postoperative and labor patients) consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine. The source and target of this ACh remain yet to be elucidated. In this study, we used an immunolabeling for choline acetyltransferase to demonstrate, for the first time, the presence of a plexus of cholinergic fibers in laminae II-III of the dorsal horn of the macaque monkey. Moreover, we show the presence of numerous cholinergic cell bodies within the same laminae and compared their density and morphological properties with those previously described in rodents. An electron microscopy analysis demonstrates that cholinergic boutons are presynaptic to dorsal horn neurons as well as to the terminals of sensory primary afferents, suggesting that they are likely to modulate incoming somatosensory information. Our data suggest that this newly identified dorsal horn cholinergic system in monkeys is the source of the ACh involved in the analgesic effects of epidural neostigmine and could be more specifically targeted for novel therapeutic strategies for pain management in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23447584      PMCID: PMC6619320          DOI: 10.1523/JNEUROSCI.3954-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  7 in total

Review 1.  PKCγ interneurons, a gateway to pathological pain in the dorsal horn.

Authors:  Alain Artola; Daniel Voisin; Radhouane Dallel
Journal:  J Neural Transm (Vienna)       Date:  2020-02-27       Impact factor: 3.575

2.  Convergence of peptidergic and non-peptidergic protein markers in the human dorsal root ganglion and spinal dorsal horn.

Authors:  Stephanie I Shiers; Ishwarya Sankaranarayanan; Vivek Jeevakumar; Anna Cervantes; Jeffrey C Reese; Theodore J Price
Journal:  J Comp Neurol       Date:  2021-02-16       Impact factor: 3.028

Review 3.  The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades.

Authors:  Gabriela Rocha Lauretti
Journal:  Saudi J Anaesth       Date:  2015-01

Review 4.  Studying human nociceptors: from fundamentals to clinic.

Authors:  Steven J Middleton; Allison M Barry; Maddalena Comini; Yan Li; Pradipta R Ray; Stephanie Shiers; Andreas C Themistocleous; Megan L Uhelski; Xun Yang; Patrick M Dougherty; Theodore J Price; David L Bennett
Journal:  Brain       Date:  2021-06-22       Impact factor: 15.255

5.  Optimal single-dose epidural neostigmine for postoperative analgesia after partial hepatectomy.

Authors:  Qiao Sheng Zhong; Sheng Jin Ge; Bei Wang; Zhang Gang Xue
Journal:  Indian J Pharmacol       Date:  2014 Nov-Dec       Impact factor: 1.200

6.  Comparison between the intravenous and caudal routes of sufentanil in children undergoing orchidopexy and further evaluation of the association of caudal adrenaline and neostigmine.

Authors:  Gabriela Rocha Lauretti; Vera Maria Silveira de Azevedo; Bruno Carvalho Portes Lopes; Anita Leocadia de Mattos
Journal:  Saudi J Anaesth       Date:  2014-07

Review 7.  Molecular, Cellular and Circuit Basis of Cholinergic Modulation of Pain.

Authors:  Paul V Naser; Rohini Kuner
Journal:  Neuroscience       Date:  2017-09-08       Impact factor: 3.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.